We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.00 | 0.55% | 1,829.00 | 1,828.00 | 1,830.00 | 1,838.00 | 1,815.00 | 1,818.00 | 79,029 | 13:17:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.02 | 4.04B |
From Apr 2019 to Apr 2024
By Ian Walker
Hikma Pharmaceuticals PLC said Tuesday that it has entered into a preliminary agreement with GlaxoSmithKline PLC's Egyptian subsidiary to buy certain businesses, and expects to start due diligence in order to proceed with talks.
The pharmaceutical group said talks relate to the potential acquisition of Glaxo's pharmaceutical and consumer commercialization and manufacturing business in Egypt, and pharmaceutical business in Tunisia.
Hikma said that any deal is subject to a number of conditions, and that there is no certainty any deal will be struck.
Hikma shares at 0810 GMT were up 1.0 pence, or 0.04%, at 2,495.0 pence.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 26, 2021 03:30 ET (08:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
